
The European Medicines Agency (EMA) has begun a risk/benefit analysis of using Danish biotech firm Bavarian Nordic’s smallpox vaccine against monkeypox, according to a press release from Sweden’s prime minister’s office.
According to the statement, the analysis will act as guidelines in connection with deciding a shared European vaccine supply purchase.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app